Evaluation of the prognostic value of the ESTRO EORTC classification of oligometastatic disease in patients treated with stereotactic body radiotherapy: A retrospective single center study

Jonas Willmann(Memorial Sloan Kettering Cancer Center), Nicolaus Andratschke(University Hospital of Zurich), Matthias Gückenberger(University Hospital of Zurich), Sebastian M. Christ(University of Zurich), Maiwand Ahmadsei(University Hospital of Zurich), Eugenia Vlaskou Badra(University Hospital of Zurich), Stephanie Kroeze(University Hospital of Zurich), Selma Adilovic(University of Zurich), Michael Mayinger(University Hospital of Zurich), Janita E. van Timmeren(University of Zurich)
Radiotherapy and Oncology
January 29, 2022
10.1016/j.radonc.2022.01.019
Cited by 46

Related Papers

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
|Annals of Oncology|2021|577
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
|Annals of Oncology|2020|232
Radiographic changes after lung stereotactic ablative radiotherapy (SABR) – Can we distinguish recurrence from fibrosis? A systematic review of the literature
|Radiotherapy and Oncology|2012|230